Gene symbol: CXCL8

Also known as: IL8; NAF; GCP1; LECT; LUCT; NAP1; GCP-1; LYNAP; MDNCF; MONAP; NAP-1; SCYB8

Organism: Homo sapiens

Summary: The protein encoded by this gene is a member of the CXC chemokine family and is a major mediator of the inflammatory response. The encoded protein is commonly referred to as interleukin-8 (IL-8). IL-8 is secreted by mononuclear macrophages, neutrophils, eosinophils, T lymphocytes, epithelial cells, and fibroblasts. It functions as a chemotactic factor by guiding the neutrophils to the site of infection. Bacterial and viral products rapidly induce IL-8 expression. IL-8 also participates with other cytokines in the proinflammatory signaling cascade and plays a role in systemic inflammatory response syndrome (SIRS). This gene is believed to play a role in the pathogenesis of the lower respiratory tract infection bronchiolitis, a common respiratory tract disease caused by the respiratory syncytial virus (RSV). The overproduction of this proinflammatory protein is thought to cause the lung inflammation associated with csytic fibrosis. This proinflammatory protein is also suspected of playing a role in coronary artery disease and endothelial dysfunction. This protein is also secreted by tumor cells and promotes tumor migration, invasion, angiogenesis and metastasis. This chemokine is also a potent angiogenic factor. The binding of IL-8 to one of its receptors (IL-8RB/CXCR2) increases the permeability of blood vessels and increasing levels of IL-8 are positively correlated with increased severity of multiple disease outcomes (eg, sepsis). This gene and other members of the CXC chemokine gene family form a gene cluster in a region of chromosome 4q. [provided by RefSeq, May 2020]

NCBI gene ID: 3576 Ensembl:ENSG00000169429 MIM:146930 AllianceGenome:HGNC:6025


GO Annotation


Category Term ID Term description
Process GO:0001775 Cell activation
Process GO:0002237 Response to molecule of bacterial origin
Process GO:0002274 Myeloid leukocyte activation
Process GO:0002376 Immune system process
Process GO:0002682 Regulation of immune system process
Process GO:0002684 Positive regulation of immune system process
Process GO:0002685 Regulation of leukocyte migration
Process GO:0002687 Positive regulation of leukocyte migration
Process GO:0002688 Regulation of leukocyte chemotaxis
Process GO:0002690 Positive regulation of leukocyte chemotaxis
Process GO:0006810 Transport
Process GO:0006897 Endocytosis
Process GO:0006898 Receptor-mediated endocytosis
Process GO:0006935 Chemotaxis
Process GO:0006950 Response to stress
Process GO:0006952 Defense response
Process GO:0006954 Inflammatory response
Process GO:0006955 Immune response
Process GO:0007154 Cell communication
Process GO:0007165 Signal transduction
Process GO:0007275 Multicellular organism development
Process GO:0008277 Regulation of G protein-coupled receptor signaling pathway
Process GO:0009605 Response to external stimulus
Process GO:0009607 Response to biotic stimulus
Process GO:0009617 Response to bacterium
Process GO:0009719 Response to endogenous stimulus
Process GO:0009790 Embryo development
Process GO:0009889 Regulation of biosynthetic process
Process GO:0009891 Positive regulation of biosynthetic process
Process GO:0009892 Negative regulation of metabolic process
Process GO:0009893 Positive regulation of metabolic process
Process GO:0009966 Regulation of signal transduction
Process GO:0009968 Negative regulation of signal transduction
Process GO:0009987 Cellular process
Process GO:0010033 Response to organic substance
Process GO:0010468 Regulation of gene expression
Process GO:0010604 Positive regulation of macromolecule metabolic process
Process GO:0010605 Negative regulation of macromolecule metabolic process
Process GO:0010628 Positive regulation of gene expression
Process GO:0010629 Negative regulation of gene expression
Process GO:0010646 Regulation of cell communication
Process GO:0010648 Negative regulation of cell communication
Process GO:0016192 Vesicle-mediated transport
Process GO:0016477 Cell migration
Process GO:0019222 Regulation of metabolic process
Process GO:0022603 Regulation of anatomical structure morphogenesis
Process GO:0023051 Regulation of signaling
Process GO:0023052 Signaling
Process GO:0023057 Negative regulation of signaling
Process GO:0030155 Regulation of cell adhesion
Process GO:0030334 Regulation of cell migration
Process GO:0030335 Positive regulation of cell migration
Process GO:0030593 Neutrophil chemotaxis
Process GO:0030595 Leukocyte chemotaxis
Process GO:0031323 Regulation of cellular metabolic process
Process GO:0031325 Positive regulation of cellular metabolic process
Process GO:0031326 Regulation of cellular biosynthetic process
Process GO:0031328 Positive regulation of cellular biosynthetic process
Process GO:0031623 Receptor internalization
Process GO:0032101 Regulation of response to external stimulus
Process GO:0032103 Positive regulation of response to external stimulus
Process GO:0032496 Response to lipopolysaccharide
Process GO:0032501 Multicellular organismal process
Process GO:0032502 Developmental process
Process GO:0033554 Cellular response to stress
Process GO:0033993 Response to lipid
Process GO:0034097 Response to cytokine
Process GO:0034612 Response to tumor necrosis factor
Process GO:0034976 Response to endoplasmic reticulum stress
Process GO:0035295 Tube development
Process GO:0035556 Intracellular signal transduction
Process GO:0036230 Granulocyte activation
Process GO:0040011 Locomotion
Process GO:0040012 Regulation of locomotion
Process GO:0040017 Positive regulation of locomotion
Process GO:0042119 Neutrophil activation
Process GO:0042221 Response to chemical
Process GO:0042330 Taxis
Process GO:0043207 Response to external biotic stimulus
Process GO:0043903 Regulation of biological process involved in symbiotic interaction
Process GO:0044344 Cellular response to fibroblast growth factor stimulus
Process GO:0044419 Biological process involved in interspecies interaction between organisms
Process GO:0045069 Regulation of viral genome replication
Process GO:0045091 Regulation of single stranded viral RNA replication via double stranded DNA intermediate
Process GO:0045321 Leukocyte activation
Process GO:0045744 Negative regulation of G protein-coupled receptor signaling pathway
Process GO:0045765 Regulation of angiogenesis
Process GO:0045766 Positive regulation of angiogenesis
Process GO:0048513 Animal organ development
Process GO:0048518 Positive regulation of biological process
Process GO:0048519 Negative regulation of biological process
Process GO:0048522 Positive regulation of cellular process
Process GO:0048523 Negative regulation of cellular process
Process GO:0048565 Digestive tract development
Process GO:0048566 Embryonic digestive tract development
Process GO:0048568 Embryonic organ development
Process GO:0048583 Regulation of response to stimulus
Process GO:0048584 Positive regulation of response to stimulus
Process GO:0048585 Negative regulation of response to stimulus
Process GO:0048731 System development
Process GO:0048856 Anatomical structure development
Process GO:0048870 Cell motility
Process GO:0050789 Regulation of biological process
Process GO:0050792 Regulation of viral process
Process GO:0050793 Regulation of developmental process
Process GO:0050794 Regulation of cellular process
Process GO:0050896 Response to stimulus
Process GO:0050900 Leukocyte migration
Process GO:0050920 Regulation of chemotaxis
Process GO:0050921 Positive regulation of chemotaxis
Process GO:0050926 Regulation of positive chemotaxis
Process GO:0050927 Positive regulation of positive chemotaxis
Process GO:0050930 Induction of positive chemotaxis
Process GO:0051094 Positive regulation of developmental process
Process GO:0051179 Localization
Process GO:0051234 Establishment of localization
Process GO:0051239 Regulation of multicellular organismal process
Process GO:0051240 Positive regulation of multicellular organismal process
Process GO:0051707 Response to other organism
Process GO:0051716 Cellular response to stimulus
Process GO:0052372 Modulation by symbiont of entry into host
Process GO:0055123 Digestive system development
Process GO:0060255 Regulation of macromolecule metabolic process
Process GO:0060326 Cell chemotaxis
Process GO:0060353 Regulation of cell adhesion molecule production
Process GO:0060354 Negative regulation of cell adhesion molecule production
Process GO:0065007 Biological regulation
Process GO:0070555 Response to interleukin-1
Process GO:0070848 Response to growth factor
Process GO:0070887 Cellular response to chemical stimulus
Process GO:0071216 Cellular response to biotic stimulus
Process GO:0071219 Cellular response to molecule of bacterial origin
Process GO:0071222 Cellular response to lipopolysaccharide
Process GO:0071310 Cellular response to organic substance
Process GO:0071345 Cellular response to cytokine stimulus
Process GO:0071347 Cellular response to interleukin-1
Process GO:0071356 Cellular response to tumor necrosis factor
Process GO:0071363 Cellular response to growth factor stimulus
Process GO:0071396 Cellular response to lipid
Process GO:0071495 Cellular response to endogenous stimulus
Process GO:0071621 Granulocyte chemotaxis
Process GO:0071622 Regulation of granulocyte chemotaxis
Process GO:0071624 Positive regulation of granulocyte chemotaxis
Process GO:0071774 Response to fibroblast growth factor
Process GO:0090022 Regulation of neutrophil chemotaxis
Process GO:0090023 Positive regulation of neutrophil chemotaxis
Process GO:0097529 Myeloid leukocyte migration
Process GO:0097530 Granulocyte migration
Process GO:1901342 Regulation of vasculature development
Process GO:1901700 Response to oxygen-containing compound
Process GO:1901701 Cellular response to oxygen-containing compound
Process GO:1902622 Regulation of neutrophil migration
Process GO:1902624 Positive regulation of neutrophil migration
Process GO:1903900 Regulation of viral life cycle
Process GO:1904018 Positive regulation of vasculature development
Process GO:1990266 Neutrophil migration
Process GO:2000026 Regulation of multicellular organismal development
Process GO:2000145 Regulation of cell motility
Process GO:2000147 Positive regulation of cell motility
Process GO:2000535 Regulation of entry of bacterium into host cell
Component GO:0005576 Extracellular region
Component GO:0005615 Extracellular space
Component GO:0110165 Cellular anatomical entity
Function GO:0001664 G protein-coupled receptor binding
Function GO:0005102 Signaling receptor binding
Function GO:0005125 Cytokine activity
Function GO:0005126 Cytokine receptor binding
Function GO:0005153 interleukin-8 receptor binding
Function GO:0005488 Binding
Function GO:0005515 Protein binding
Function GO:0005539 Glycosaminoglycan binding
Function GO:0008009 Chemokine activity
Function GO:0008201 Heparin binding
Function GO:0030545 Signaling receptor regulator activity
Function GO:0030546 Signaling receptor activator activity
Function GO:0042379 Chemokine receptor binding
Function GO:0045236 CXCR chemokine receptor binding
Function GO:0048018 Receptor ligand activity
Function GO:0097367 Carbohydrate derivative binding
Function GO:0098772 Molecular function regulator activity
Function GO:1901681 Sulfur compound binding
Process GO:0001525 Angiogenesis
Process GO:0001568 Blood vessel development
Process GO:0001775 Cell activation
Process GO:0001906 Cell killing
Process GO:0001944 Vasculature development
Process GO:0002237 Response to molecule of bacterial origin
Process GO:0002274 Myeloid leukocyte activation
Process GO:0002376 Immune system process
Process GO:0002682 Regulation of immune system process
Process GO:0002684 Positive regulation of immune system process
Process GO:0002685 Regulation of leukocyte migration
Process GO:0002687 Positive regulation of leukocyte migration
Process GO:0002688 Regulation of leukocyte chemotaxis
Process GO:0002690 Positive regulation of leukocyte chemotaxis
Process GO:0006810 Transport
Process GO:0006897 Endocytosis
Process GO:0006898 Receptor-mediated endocytosis
Process GO:0006935 Chemotaxis
Process GO:0006950 Response to stress
Process GO:0006952 Defense response
Process GO:0006954 Inflammatory response
Process GO:0006955 Immune response
Process GO:0006959 Humoral immune response
Process GO:0007154 Cell communication
Process GO:0007165 Signal transduction
Process GO:0007166 Cell surface receptor signaling pathway
Process GO:0007186 G protein-coupled receptor signaling pathway
Process GO:0007275 Multicellular organism development
Process GO:0008277 Regulation of G protein-coupled receptor signaling pathway
Process GO:0008285 Negative regulation of cell population proliferation
Process GO:0009605 Response to external stimulus
Process GO:0009607 Response to biotic stimulus
Process GO:0009617 Response to bacterium
Process GO:0009653 Anatomical structure morphogenesis
Process GO:0009719 Response to endogenous stimulus
Process GO:0009790 Embryo development
Process GO:0009889 Regulation of biosynthetic process
Process GO:0009891 Positive regulation of biosynthetic process
Process GO:0009892 Negative regulation of metabolic process
Process GO:0009893 Positive regulation of metabolic process
Process GO:0009966 Regulation of signal transduction
Process GO:0009968 Negative regulation of signal transduction
Process GO:0009987 Cellular process
Process GO:0010033 Response to organic substance
Process GO:0010468 Regulation of gene expression
Process GO:0010604 Positive regulation of macromolecule metabolic process
Process GO:0010605 Negative regulation of macromolecule metabolic process
Process GO:0010628 Positive regulation of gene expression
Process GO:0010629 Negative regulation of gene expression
Process GO:0010646 Regulation of cell communication
Process GO:0010648 Negative regulation of cell communication
Process GO:0016192 Vesicle-mediated transport
Process GO:0016477 Cell migration
Process GO:0019221 Cytokine-mediated signaling pathway
Process GO:0019222 Regulation of metabolic process
Process GO:0019722 Calcium-mediated signaling
Process GO:0019730 Antimicrobial humoral response
Process GO:0019932 Second-messenger-mediated signaling
Process GO:0022603 Regulation of anatomical structure morphogenesis
Process GO:0023051 Regulation of signaling
Process GO:0023052 Signaling
Process GO:0023057 Negative regulation of signaling
Process GO:0030155 Regulation of cell adhesion
Process GO:0030334 Regulation of cell migration
Process GO:0030335 Positive regulation of cell migration
Process GO:0030593 Neutrophil chemotaxis
Process GO:0030595 Leukocyte chemotaxis
Process GO:0031323 Regulation of cellular metabolic process
Process GO:0031325 Positive regulation of cellular metabolic process
Process GO:0031326 Regulation of cellular biosynthetic process
Process GO:0031328 Positive regulation of cellular biosynthetic process
Process GO:0031623 Receptor internalization
Process GO:0031640 Killing of cells of another organism
Process GO:0032101 Regulation of response to external stimulus
Process GO:0032103 Positive regulation of response to external stimulus
Process GO:0032496 Response to lipopolysaccharide
Process GO:0032501 Multicellular organismal process
Process GO:0032502 Developmental process
Process GO:0033554 Cellular response to stress
Process GO:0033993 Response to lipid
Process GO:0034097 Response to cytokine
Process GO:0034612 Response to tumor necrosis factor
Process GO:0034976 Response to endoplasmic reticulum stress
Process GO:0035239 Tube morphogenesis
Process GO:0035295 Tube development
Process GO:0035556 Intracellular signal transduction
Process GO:0036230 Granulocyte activation
Process GO:0040011 Locomotion
Process GO:0040012 Regulation of locomotion
Process GO:0040017 Positive regulation of locomotion
Process GO:0042119 Neutrophil activation
Process GO:0042127 Regulation of cell population proliferation
Process GO:0042221 Response to chemical
Process GO:0042330 Taxis
Process GO:0043207 Response to external biotic stimulus
Process GO:0043903 Regulation of biological process involved in symbiotic interaction
Process GO:0044344 Cellular response to fibroblast growth factor stimulus
Process GO:0044419 Biological process involved in interspecies interaction between organisms
Process GO:0045069 Regulation of viral genome replication
Process GO:0045091 Regulation of single stranded viral RNA replication via double stranded DNA intermediate
Process GO:0045321 Leukocyte activation
Process GO:0045744 Negative regulation of G protein-coupled receptor signaling pathway
Process GO:0045765 Regulation of angiogenesis
Process GO:0045766 Positive regulation of angiogenesis
Process GO:0048513 Animal organ development
Process GO:0048514 Blood vessel morphogenesis
Process GO:0048518 Positive regulation of biological process
Process GO:0048519 Negative regulation of biological process
Process GO:0048522 Positive regulation of cellular process
Process GO:0048523 Negative regulation of cellular process
Process GO:0048565 Digestive tract development
Process GO:0048566 Embryonic digestive tract development
Process GO:0048568 Embryonic organ development
Process GO:0048583 Regulation of response to stimulus
Process GO:0048584 Positive regulation of response to stimulus
Process GO:0048585 Negative regulation of response to stimulus
Process GO:0048646 Anatomical structure formation involved in morphogenesis
Process GO:0048731 System development
Process GO:0048856 Anatomical structure development
Process GO:0048870 Cell motility
Process GO:0050789 Regulation of biological process
Process GO:0050792 Regulation of viral process
Process GO:0050793 Regulation of developmental process
Process GO:0050794 Regulation of cellular process
Process GO:0050896 Response to stimulus
Process GO:0050900 Leukocyte migration
Process GO:0050920 Regulation of chemotaxis
Process GO:0050921 Positive regulation of chemotaxis
Process GO:0050926 Regulation of positive chemotaxis
Process GO:0050927 Positive regulation of positive chemotaxis
Process GO:0050930 Induction of positive chemotaxis
Process GO:0051094 Positive regulation of developmental process
Process GO:0051179 Localization
Process GO:0051234 Establishment of localization
Process GO:0051239 Regulation of multicellular organismal process
Process GO:0051240 Positive regulation of multicellular organismal process
Process GO:0051707 Response to other organism
Process GO:0051716 Cellular response to stimulus
Process GO:0052372 Modulation by symbiont of entry into host
Process GO:0055123 Digestive system development
Process GO:0060255 Regulation of macromolecule metabolic process
Process GO:0060326 Cell chemotaxis
Process GO:0060353 Regulation of cell adhesion molecule production
Process GO:0060354 Negative regulation of cell adhesion molecule production
Process GO:0061844 Antimicrobial humoral immune response mediated by antimicrobial peptide
Process GO:0065007 Biological regulation
Process GO:0070098 Chemokine-mediated signaling pathway
Process GO:0070555 Response to interleukin-1
Process GO:0070848 Response to growth factor
Process GO:0070887 Cellular response to chemical stimulus
Process GO:0071216 Cellular response to biotic stimulus
Process GO:0071219 Cellular response to molecule of bacterial origin
Process GO:0071222 Cellular response to lipopolysaccharide
Process GO:0071310 Cellular response to organic substance
Process GO:0071345 Cellular response to cytokine stimulus
Process GO:0071347 Cellular response to interleukin-1
Process GO:0071356 Cellular response to tumor necrosis factor
Process GO:0071363 Cellular response to growth factor stimulus
Process GO:0071396 Cellular response to lipid
Process GO:0071495 Cellular response to endogenous stimulus
Process GO:0071621 Granulocyte chemotaxis
Process GO:0071622 Regulation of granulocyte chemotaxis
Process GO:0071624 Positive regulation of granulocyte chemotaxis
Process GO:0071774 Response to fibroblast growth factor
Process GO:0072359 Circulatory system development
Process GO:0090022 Regulation of neutrophil chemotaxis
Process GO:0090023 Positive regulation of neutrophil chemotaxis
Process GO:0097529 Myeloid leukocyte migration
Process GO:0097530 Granulocyte migration
Process GO:0098542 Defense response to other organism
Process GO:1901342 Regulation of vasculature development
Process GO:1901700 Response to oxygen-containing compound
Process GO:1901701 Cellular response to oxygen-containing compound
Process GO:1902622 Regulation of neutrophil migration
Process GO:1902624 Positive regulation of neutrophil migration
Process GO:1903900 Regulation of viral life cycle
Process GO:1904018 Positive regulation of vasculature development
Process GO:1990266 Neutrophil migration
Process GO:1990868 Response to chemokine
Process GO:1990869 Cellular response to chemokine
Process GO:2000026 Regulation of multicellular organismal development
Process GO:2000145 Regulation of cell motility
Process GO:2000147 Positive regulation of cell motility
Process GO:2000535 Regulation of entry of bacterium into host cell
Component GO:0005576 Extracellular region
Component GO:0005615 Extracellular space
Component GO:0110165 Cellular anatomical entity
Function GO:0001664 G protein-coupled receptor binding
Function GO:0005102 Signaling receptor binding
Function GO:0005125 Cytokine activity
Function GO:0005126 Cytokine receptor binding
Function GO:0005153 interleukin-8 receptor binding
Function GO:0005488 Binding
Function GO:0005515 Protein binding
Function GO:0005539 Glycosaminoglycan binding
Function GO:0008009 Chemokine activity
Function GO:0008201 Heparin binding
Function GO:0030545 Signaling receptor regulator activity
Function GO:0030546 Signaling receptor activator activity
Function GO:0042379 Chemokine receptor binding
Function GO:0045236 CXCR chemokine receptor binding
Function GO:0048018 Receptor ligand activity
Function GO:0097367 Carbohydrate derivative binding
Function GO:0098772 Molecular function regulator activity
Function GO:1901681 Sulfur compound binding

Pathway annotation


Category Term ID Term description
RCTM MAP-162582 Signal Transduction
RCTM MAP-372790 Signaling by GPCR
RCTM MAP-373076 Class A/1 (Rhodopsin-like receptors)
RCTM MAP-375276 Peptide ligand-binding receptors
RCTM MAP-380108 Chemokine receptors bind chemokines
RCTM MAP-388396 GPCR downstream signalling
RCTM MAP-418594 G alpha (i) signalling events
RCTM MAP-500792 GPCR ligand binding
RCTM HSA-1280215 Cytokine Signaling in Immune system
RCTM HSA-162582 Signal Transduction
RCTM HSA-168256 Immune System
RCTM HSA-2262752 Cellular responses to stress
RCTM HSA-2559582 Senescence-Associated Secretory Phenotype (SASP)
RCTM HSA-2559583 Cellular Senescence
RCTM HSA-372790 Signaling by GPCR
RCTM HSA-373076 Class A/1 (Rhodopsin-like receptors)
RCTM HSA-375276 Peptide ligand-binding receptors
RCTM HSA-380108 Chemokine receptors bind chemokines
RCTM HSA-380994 ATF4 activates genes in response to endoplasmic reticulum stress
RCTM HSA-381042 PERK regulates gene expression
RCTM HSA-381119 Unfolded Protein Response (UPR)
RCTM HSA-388396 GPCR downstream signalling
RCTM HSA-418594 G alpha (i) signalling events
RCTM HSA-449147 Signaling by Interleukins
RCTM HSA-500792 GPCR ligand binding
RCTM HSA-6783783 Interleukin-10 signaling
RCTM HSA-6785807 Interleukin-4 and Interleukin-13 signaling
RCTM HSA-8953897 Cellular responses to stimuli
WikiPathways WP2203 Thymic stromal lymphopoietin (TSLP) signaling pathway
WikiPathways WP2328 Allograft rejection
WikiPathways WP2355 Corticotropin-releasing hormone signaling pathway
WikiPathways WP2431 Spinal cord injury
WikiPathways WP262 Ebstein-Barr virus LMP1 signaling
WikiPathways WP2828 Bladder cancer
WikiPathways WP286 IL-3 signaling pathway
WikiPathways WP3287 Overview of nanoparticle effects
WikiPathways WP3617 Photodynamic therapy-induced NF-kB survival signaling
WikiPathways WP3624 Lung fibrosis
WikiPathways WP3646 Hepatitis C and hepatocellular carcinoma
WikiPathways WP3851 TLR4 signaling and tolerance
WikiPathways WP3865 Novel intracellular components of RIG-I-like receptor pathway
WikiPathways WP3888 VEGFA-VEGFR2 signaling
WikiPathways WP4329 miRNA role in immune response in sepsis
WikiPathways WP4341 Non-genomic actions of 1,25 dihydroxyvitamin D3
WikiPathways WP4396 Nonalcoholic fatty liver disease
WikiPathways WP4478 LTF danger signal response pathway
WikiPathways WP4481 Resistin as a regulator of inflammation
WikiPathways WP4493 Cells and molecules involved in local acute inflammatory response
WikiPathways WP4659 Gastrin signaling pathway
WikiPathways WP4666 Hepatitis B infection
WikiPathways WP4754 IL-18 signaling pathway
WikiPathways WP4884 Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex
WikiPathways WP4891 COVID-19 adverse outcome pathway
WikiPathways WP5039 SARS-CoV-2 innate immunity evasion and cell-specific immune response
WikiPathways WP5055 Burn wound healing
WikiPathways WP5088 Prostaglandin signaling
WikiPathways WP5095 Overview of proinflammatory and profibrotic mediators
WikiPathways WP5113 Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway
WikiPathways WP5115 Network map of SARS-CoV-2 signaling pathway
WikiPathways WP5143 GDNF signaling
WikiPathways WP5285 Immune infiltration in pancreatic cancer
WikiPathways WP706 Sudden infant death syndrome (SIDS) susceptibility pathways
WikiPathways WP75 Toll-like receptor signaling pathway
KEGG ocu04060 Cytokine-cytokine receptor interaction
KEGG ocu04061 Viral protein interaction with cytokine and cytokine receptor
KEGG ocu04062 Chemokine signaling pathway
KEGG ocu04064 NF-kappa B signaling pathway
KEGG ocu04072 Phospholipase D signaling pathway
KEGG ocu04218 Cellular senescence
KEGG ocu04620 Toll-like receptor signaling pathway
KEGG ocu04621 NOD-like receptor signaling pathway
KEGG ocu04622 RIG-I-like receptor signaling pathway
KEGG ocu04657 IL-17 signaling pathway
KEGG ocu04932 Non-alcoholic fatty liver disease
KEGG ocu04933 AGE-RAGE signaling pathway in diabetic complications
KEGG ocu04936 Alcoholic liver disease
KEGG ocu05132 Salmonella infection
KEGG ocu05133 Pertussis
KEGG ocu05134 Legionellosis
KEGG ocu05135 Yersinia infection
KEGG ocu05142 Chagas disease
KEGG ocu05144 Malaria
KEGG ocu05146 Amoebiasis
KEGG ocu05161 Hepatitis B
KEGG ocu05163 Human cytomegalovirus infection
KEGG ocu05164 Influenza A
KEGG ocu05167 Kaposi sarcoma-associated herpesvirus infection
KEGG ocu05171 Coronavirus disease - COVID-19
KEGG ocu05200 Pathways in cancer
KEGG ocu05202 Transcriptional misregulation in cancer
KEGG ocu05219 Bladder cancer
KEGG ocu05323 Rheumatoid arthritis
KEGG ocu05417 Lipid and atherosclerosis
KEGG hsa04060 Cytokine-cytokine receptor interaction
KEGG hsa04061 Viral protein interaction with cytokine and cytokine receptor
KEGG hsa04062 Chemokine signaling pathway
KEGG hsa04064 NF-kappa B signaling pathway
KEGG hsa04072 Phospholipase D signaling pathway
KEGG hsa04218 Cellular senescence
KEGG hsa04620 Toll-like receptor signaling pathway
KEGG hsa04621 NOD-like receptor signaling pathway
KEGG hsa04622 RIG-I-like receptor signaling pathway
KEGG hsa04657 IL-17 signaling pathway
KEGG hsa04932 Non-alcoholic fatty liver disease
KEGG hsa04933 AGE-RAGE signaling pathway in diabetic complications
KEGG hsa04936 Alcoholic liver disease
KEGG hsa05120 Epithelial cell signaling in Helicobacter pylori infection
KEGG hsa05130 Pathogenic Escherichia coli infection
KEGG hsa05131 Shigellosis
KEGG hsa05132 Salmonella infection
KEGG hsa05133 Pertussis
KEGG hsa05134 Legionellosis
KEGG hsa05135 Yersinia infection
KEGG hsa05142 Chagas disease
KEGG hsa05144 Malaria
KEGG hsa05146 Amoebiasis
KEGG hsa05161 Hepatitis B
KEGG hsa05163 Human cytomegalovirus infection
KEGG hsa05164 Influenza A
KEGG hsa05167 Kaposi sarcoma-associated herpesvirus infection
KEGG hsa05171 Coronavirus disease - COVID-19
KEGG hsa05200 Pathways in cancer
KEGG hsa05202 Transcriptional misregulation in cancer
KEGG hsa05219 Bladder cancer
KEGG hsa05323 Rheumatoid arthritis
KEGG hsa05417 Lipid and atherosclerosis

Expression profile of CXCL8 in omics data



ID GSE120596
Title Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction is Associated with Differences in Activation of the Cyclooxygenase Pathway
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM3405450 1001_baseline cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: baseline library barcode: ATTACTCG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 6.0
GSM3405451 1001_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1001 gender: Female timepoint: post-surgery 1 library barcode: TCCGGAGA-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 76.0
GSM3405452 1002_baseline cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: baseline library barcode: CGCTCATT-TATAGCCT drug treatment: Placebo response group: Placebo 100.0
GSM3405453 1002_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1002 gender: Female timepoint: post-surgery 1 library barcode: GAGATTCC-TATAGCCT drug treatment: Placebo response group: Placebo 115.0
GSM3405454 1003_baseline cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: baseline library barcode: ATTCAGAA-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder 23.0
GSM3405455 1003_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1003 gender: Male timepoint: post-surgery 1 library barcode: GAATTCGT-TATAGCCT drug treatment: ibuprofen sodium response group: Full responder 51.0
GSM3405456 1004_baseline cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: baseline library barcode: CTGAAGCT-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 24.0
GSM3405457 1004_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1004 gender: Male timepoint: post-surgery 1 library barcode: TAATGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder
GSM3405458 1005_baseline cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: baseline library barcode: CGGCTATG-TATAGCCT drug treatment: Placebo response group: Placebo 25.0
GSM3405459 1005_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1005 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-TATAGCCT drug treatment: Placebo response group: Placebo
GSM3405460 1006_baseline cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: baseline library barcode: TCTCGCGC-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 30.0
GSM3405461 1006_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1006 gender: Male timepoint: post-surgery 1 library barcode: AGCGATAG-TATAGCCT drug treatment: ibuprofen sodium response group: Partial responder 128.0
GSM3405462 1007_baseline cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: baseline library barcode: ATTACTCG-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405463 1007_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1007 gender: Male timepoint: post-surgery 1 library barcode: TCCGGAGA-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405464 1008_baseline cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: baseline library barcode: CGCTCATT-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405465 1008_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405466 1008_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1008 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-ATAGAGGC drug treatment: Placebo response group: Placebo
GSM3405467 1011_baseline cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: baseline library barcode: GAATTCGT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder 8.0
GSM3405468 1011_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405469 1011_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1011 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Full responder
GSM3405470 1012_baseline cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: baseline library barcode: CGGCTATG-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder 37.0
GSM3405471 1012_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder 80.0
GSM3405472 1012_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1012 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-ATAGAGGC drug treatment: ibuprofen sodium response group: Partial responder
GSM3405473 1014_baseline cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: baseline library barcode: AGCGATAG-ATAGAGGC drug treatment: Placebo response group: Placebo 21.0
GSM3405474 1014_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-CCTATCCT drug treatment: Placebo response group: Placebo 22.0
GSM3405475 1014_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1014 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-CCTATCCT drug treatment: Placebo response group: Placebo 95.0
GSM3405476 1015_baseline cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: baseline library barcode: CGCTCATT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 87.0
GSM3405477 1015_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 58.0
GSM3405478 1015_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1015 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 54.0
GSM3405479 1016_baseline cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: baseline library barcode: GAATTCGT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 43.0
GSM3405480 1016_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 40.0
GSM3405481 1016_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1016 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 42.0
GSM3405482 1017_baseline cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: baseline library barcode: CGGCTATG-CCTATCCT drug treatment: Placebo response group: Placebo 21.0
GSM3405483 1017_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 1 library barcode: TCCGCGAA-CCTATCCT drug treatment: Placebo response group: Placebo 36.0
GSM3405484 1017_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1017 gender: Male timepoint: post-surgery 2 library barcode: TCTCGCGC-CCTATCCT drug treatment: Placebo response group: Placebo 33.0
GSM3405485 1018_baseline cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: baseline library barcode: AGCGATAG-CCTATCCT drug treatment: ibuprofen sodium response group: Full responder 123.0
GSM3405486 1018_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 65.0
GSM3405487 1018_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1018 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 131.0
GSM3405488 1019_baseline cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: baseline library barcode: CGCTCATT-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 29.0
GSM3405489 1019_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 38.0
GSM3405490 1019_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1019 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 65.0
GSM3405491 1020_baseline cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: baseline library barcode: GAATTCGT-GGCTCTGA drug treatment: Placebo response group: Placebo
GSM3405492 1020_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-GGCTCTGA drug treatment: Placebo response group: Placebo 15.0
GSM3405493 1020_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1020 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-GGCTCTGA drug treatment: Placebo response group: Placebo 12.0
GSM3405494 1021_baseline cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: baseline library barcode: CGGCTATG-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 30.0
GSM3405495 1021_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 525.0
GSM3405496 1021_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1021 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-GGCTCTGA drug treatment: ibuprofen sodium response group: Partial responder 258.0
GSM3405497 1022_baseline cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: baseline library barcode: AGCGATAG-GGCTCTGA drug treatment: ibuprofen sodium response group: Full responder 69.0
GSM3405498 1022_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 1 library barcode: ATTACTCG-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder 61.0
GSM3405499 1022_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1022 gender: Male timepoint: post-surgery 2 library barcode: TCCGGAGA-AGGCGAAG drug treatment: ibuprofen sodium response group: Full responder 85.0
GSM3405500 1023_baseline cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: baseline library barcode: CGCTCATT-AGGCGAAG drug treatment: Placebo response group: Placebo 63.0
GSM3405501 1023_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-AGGCGAAG drug treatment: Placebo response group: Placebo 138.0
GSM3405502 1023_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1023 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-AGGCGAAG drug treatment: Placebo response group: Placebo 74.0
GSM3405503 1024_baseline cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: baseline library barcode: GAATTCGT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 158.0
GSM3405504 1024_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 1 library barcode: CTGAAGCT-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 73.0
GSM3405505 1024_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1024 gender: Female timepoint: post-surgery 2 library barcode: TAATGCGC-AGGCGAAG drug treatment: ibuprofen sodium response group: Partial responder 101.0
GSM3405506 1026_baseline cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: baseline library barcode: CGGCTATG-AGGCGAAG drug treatment: Placebo response group: Placebo 3.0
GSM3405507 1026_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-AGGCGAAG drug treatment: Placebo response group: Placebo 56.0
GSM3405508 1026_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1026 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-AGGCGAAG drug treatment: Placebo response group: Placebo 23.0
GSM3405509 1027_baseline cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: baseline library barcode: AGCGATAG-AGGCGAAG drug treatment: Placebo response group: Placebo 56.0
GSM3405510 1027_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-TAATCTTA drug treatment: Placebo response group: Placebo 303.0
GSM3405511 1027_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1027 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-TAATCTTA drug treatment: Placebo response group: Placebo 119.0
GSM3405512 1028_baseline cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: baseline library barcode: CGCTCATT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 20.0
GSM3405513 1028_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 54.0
GSM3405514 1028_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1028 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 220.0
GSM3405515 1029_baseline cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: baseline library barcode: GAATTCGT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 23.0
GSM3405516 1029_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 1 library barcode: CTGAAGCT-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 7.0
GSM3405517 1029_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1029 gender: Male timepoint: post-surgery 2 library barcode: TAATGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 62.0
GSM3405518 1030_baseline cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: baseline library barcode: CGGCTATG-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 2.0
GSM3405519 1030_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 1 library barcode: TCCGCGAA-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 30.0
GSM3405520 1030_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1030 gender: Female timepoint: post-surgery 2 library barcode: TCTCGCGC-TAATCTTA drug treatment: ibuprofen sodium response group: Partial responder 14.0
GSM3405521 1032_baseline cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: baseline library barcode: AGCGATAG-TAATCTTA drug treatment: Placebo response group: Placebo 16.0
GSM3405522 1032_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 1 library barcode: ATTACTCG-CAGGACGT drug treatment: Placebo response group: Placebo 9.0
GSM3405523 1032_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1032 gender: Female timepoint: post-surgery 2 library barcode: TCCGGAGA-CAGGACGT drug treatment: Placebo response group: Placebo 36.0
GSM3405524 1033_baseline cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: baseline library barcode: CGCTCATT-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 21.0
GSM3405525 1033_post-surgery_1 cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 1 library barcode: GAGATTCC-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 6.0
GSM3405526 1033_post-surgery_2 cell type: peripheral blood mononuclear cell subject: 1033 gender: Male timepoint: post-surgery 2 library barcode: ATTCAGAA-CAGGACGT drug treatment: ibuprofen sodium response group: Full responder 9.0

ID GSE12860
Title Antirheumatic Drug Response in Human Chondrocytes: Potential Molecular Targets to Stimulate Cartilage Regeneration
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM322609 RASF stimulated chondrocytes rep 1 GSM253283 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium 11.92103252
GSM322610 RASF stimulated chondrocytes rep 2 GSM253284 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium 12.24747295
GSM322611 NDSF stimulated chondrocytes rep 1 GSM253285 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium 10.2895568
GSM322612 NDSF stimulated chondrocytes rep 2 GSM253286 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of NDSF cultured in the same medium 10.806194925
GSM322613 Chondrocytes stimulated with diclofenac treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h 11.198196639999999
GSM322614 Chondrocytes stimulated with diclofenac treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with diclofenac for 48h 11.17264818
GSM322615 Chondrocytes stimulated with prioxicam treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h 9.6231104105
GSM322616 Chondrocytes stimulated with prioxicam treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with piroxicam for 48h 9.0402081505
GSM322617 Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h 11.472039559999999
GSM322618 Chondrocytes stimulated with chloroquine phosphate (resochin) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with chloroquine phosphate (resochin) for 48h 11.798042594999998
GSM322619 Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h 9.118959529
GSM322620 Chondrocytes stimulated with sodium aurothiomalate (tauredon) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with sodium aurothiomalate (tauredon) for 48h 9.612837605500001
GSM322621 Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h 10.076069303499999
GSM322622 Chondrocytes stimulated with azathioprine (imurek) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with azathioprine (imurek) for 48h 10.21985656
GSM322623 Chondrocytes stimulated with methotrexate treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h 9.5388387695
GSM322624 Chondrocytes stimulated with methotrexate treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methotrexate for 48h 9.7827289545
GSM322625 Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h 7.9522890760000005
GSM322626 Chondrocytes stimulated with prednisolone (solu-decortin) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with prednisolone (solu-decortin) for 48h 8.237431632
GSM322627 Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 1 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h 7.991625071500001
GSM322628 Chondrocytes stimulated with methylprednisolone (urbason) treated RASF rep 2 Human chondrocytes cultured in RPMI 1640 medium supplemented with 10% human serum, 100ng/ml amphotericin B, 100U/ml penicillin and 100µg/ml streptomycin for 2 passages, 3D cultured for 14 days in alginate beads in presence of 170µM L-ascorbic acid 2-phosphate and subsequently stimulated for 48h with supernatant of RASF cultured in the same medium and treated with methylprednisolone (urbason) for 48h 6.5523824049999995

ID GSE150408
Title Identification of key genes potentially related to intervertebral disc degeneration by microarray analysis
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM4548691 volunteer-9 tissue: whole blood diagnosis: healthy control treatment: n/a 6.108839998
GSM4548692 volunteer-10 tissue: whole blood diagnosis: healthy control treatment: n/a 5.083315037
GSM4548693 volunteer-11 tissue: whole blood diagnosis: healthy control treatment: n/a 4.255565441
GSM4548694 volunteer-12 tissue: whole blood diagnosis: healthy control treatment: n/a 3.726415165
GSM4548695 volunteer-13 tissue: whole blood diagnosis: healthy control treatment: n/a 5.37892956
GSM4548696 volunteer-14 tissue: whole blood diagnosis: healthy control treatment: n/a 6.55880586
GSM4548697 volunteer-15 tissue: whole blood diagnosis: healthy control treatment: n/a 4.445787265
GSM4548698 volunteer-16 tissue: whole blood diagnosis: healthy control treatment: n/a 4.86200342
GSM4548699 volunteer-17 tissue: whole blood diagnosis: healthy control treatment: n/a 4.144440839
GSM4548700 volunteer-18 tissue: whole blood diagnosis: healthy control treatment: n/a 3.366651404
GSM4548701 volunteer-19 tissue: whole blood diagnosis: healthy control treatment: n/a 5.918384622
GSM4548702 volunteer-20 tissue: whole blood diagnosis: healthy control treatment: n/a 4.966418254
GSM4548703 volunteer-21 tissue: whole blood diagnosis: healthy control treatment: n/a 5.806155413
GSM4548704 volunteer-22 tissue: whole blood diagnosis: healthy control treatment: n/a 1.691781894
GSM4548705 volunteer-23 tissue: whole blood diagnosis: healthy control treatment: n/a 3.351272581
GSM4548706 volunteer-24 tissue: whole blood diagnosis: healthy control treatment: n/a 3.09988177
GSM4548707 volunteer-25 tissue: whole blood diagnosis: healthy control treatment: n/a 2.081241476
GSM4548708 patient-9 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.895111555
GSM4548709 patient-10 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 5.87501534
GSM4548710 patient-11 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 5.021124642
GSM4548711 patient-12 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 5.937169271
GSM4548712 patient-13 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.317359504
GSM4548713 patient-14 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.82966607
GSM4548714 patient-15 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.795448608
GSM4548715 patient-16 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.814833757
GSM4548716 patient-17 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.428050649
GSM4548717 patient-18 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.96076146
GSM4548718 patient-19 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.577700112
GSM4548719 patient-20 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 4.329957613
GSM4548720 patient-21 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.413099949
GSM4548721 patient-22 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.651026118
GSM4548722 patient-23 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.556903232
GSM4548723 patient-24 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.248023973
GSM4548724 patient-25 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: none 3.755916505
GSM4548725 treatment-1 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 5.001710911
GSM4548726 treatment-2 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.85652392
GSM4548727 treatment-3 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 5.896159336
GSM4548728 treatment-4 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 5.617819916
GSM4548729 treatment-5 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.433360189
GSM4548730 treatment-6 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.746840096
GSM4548731 treatment-7 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 5.576322473
GSM4548732 treatment-8 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.620436362
GSM4548733 treatment-9 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 5.749475214
GSM4548734 treatment-10 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.352327583
GSM4548735 treatment-11 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 5.05300955
GSM4548736 treatment-12 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.644094303
GSM4548737 treatment-13 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.383003217
GSM4548738 treatment-14 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.307909343
GSM4548739 treatment-15 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.767965667
GSM4548740 treatment-16 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.67890334
GSM4548741 treatment-17 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 3.585177909
GSM4548742 treatment-18 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 2.143819176
GSM4548743 treatment-19 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 5.317501523
GSM4548744 treatment-20 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.295395988
GSM4548745 treatment-21 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.280831915
GSM4548746 treatment-22 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.201322786
GSM4548747 treatment-23 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 6.247319601
GSM4548748 treatment-24 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.902648291
GSM4548749 treatment-25 tissue: whole blood diagnosis: intervertebral disc degeneration treatment: Traditional Chinese Medicine 4.62021446

ID GSE166193
Title Expression data from human astrocytes (HA) under oxygen-glucose deprivation / reoxygenation
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM5065655 without DEX pretreatment, reoxygenation time is 0 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 0 h tissue: brain 6.33351
GSM5065656 without DEX pretreatment, reoxygenation time is 2 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 2 h tissue: brain 9.07726
GSM5065657 without DEX pretreatment, reoxygenation time is 6 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 6 h tissue: brain 6.61786
GSM5065658 without DEX pretreatment, reoxygenation time is 12 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 12 h tissue: brain 7.18583
GSM5065659 without DEX pretreatment, reoxygenation time is 24 h cell type: astrocyte treatment: without DEX pretreatment and reoxygenated for 24 h tissue: brain 5.68449
GSM5065660 with DEX pretreatment, reoxygenation time is 0 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 0 h tissue: brain 6.3472
GSM5065661 with DEX pretreatment, reoxygenation time is 2 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 2 h tissue: brain 8.82417
GSM5065662 with DEX pretreatment, reoxygenation time is 6 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 6 h tissue: brain 6.67084
GSM5065663 with DEX pretreatment, reoxygenation time is 12 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 12 h tissue: brain 7.61931
GSM5065664 with DEX pretreatment, reoxygenation time is 24 h cell type: astrocyte treatment: with DEX pretreatment and reoxygenated for 24 h tissue: brain 6.93892
GSM5065665 control cell type: astrocyte treatment: without stress tissue: brain 4.11697

ID GSE179004
Title Expression data from glioblastoma surgical specimens
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM5403447 glioblastoma tissue 1 in TIVA group tissue: glioblastoma 10.61026405
GSM5403448 glioblastoma tissue 2 in TIVA group tissue: glioblastoma 6.870179413
GSM5403449 glioblastoma tissue 3 in TIVA group tissue: glioblastoma 4.485000427
GSM5403450 glioblastoma tissue 1 in INHA group tissue: glioblastoma 3.529673192
GSM5403451 glioblastoma tissue 2 in INHA group tissue: glioblastoma 4.988860405
GSM5403452 glioblastoma tissue 3 in INHA group tissue: glioblastoma 4.480768309

ID GSE212044
Title Reversibility of etomidate-induced contractile arrest through activation of myocardial autophagy
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM6508421 IPSC-CM cells, DSMO 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 6.0
GSM6508422 IPSC-CM cells, DSMO 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 14.0
GSM6508423 IPSC-CM cells, DSMO 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: DSMO time: Day 30 10.0
GSM6508424 IPSC-CM cells, Etomidate 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 2.0
GSM6508425 IPSC-CM cells, Etomidate 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 5.0
GSM6508426 IPSC-CM cells, Etomidate 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Etomidate time: Day 30 8.0
GSM6508427 IPSC-CM cells, Propofol 1 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 13.0
GSM6508428 IPSC-CM cells, Propofol 2 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 7.0
GSM6508429 IPSC-CM cells, Propofol 3 cell line: Induced pluripotent stem cells (IPSC) cell type: iPSC-derived Cardiomyocytes(IPSC-CM) phenotype: dilated (DCM) disease state: Duchenne Muscular Dystrophy (DMD) treatment: Propofol time: Day 30 9.0

ID GSE255952
Title Transcriptome data of B cells and T helper cells from patients with multiple sclerosis receiving methylprednisolone for the treatment of an acute relapse
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM8083291 patient C1P1, before first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 34.9 cells per ml: 2982000 purity (%): 98.1 rna integrity number: 7.8 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 5.25524
GSM8083292 patient C1P1, after first course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 25.9 cells per ml: 304500 purity (%): 95.3 rna integrity number: 8.7 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 133 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: hair loss 4.66091
GSM8083293 patient C1P1, before second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.8 cells per ml: 1254750 purity (%): 96.7 rna integrity number: 8.3 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: 3.5 disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 5.00562
GSM8083294 patient C1P1, after second course of MP, T cells tissue: peripheral blood patient id: C1P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.6 cells per ml: 231000 purity (%): 93.7 rna integrity number: 9.4 age (years): 60 Sex: female body weight (in kg): 75.4 body size (in cm): 168 body mass index: 26.7 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 11 number of relapses in the past 2 years: 0 duration since last relapse (months): 134 edss score: NA disease-modifying therapy: teriflunomide number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: worse fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 2 side effects to mp: headache, diarrhea 4.15571
GSM8083295 patient C1P2, before first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 4.7 cells per ml: 236250 purity (%): 91.9 rna integrity number: 9.0 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 8.10097
GSM8083296 patient C1P2, after first course of MP, B cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 3.7 cells per ml: 283500 purity (%): 91.0 rna integrity number: 9.1 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 9.11043
GSM8083297 patient C1P2, before first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 28.7 cells per ml: 693000 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: yes fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 4.7271
GSM8083298 patient C1P2, after first course of MP, T cells tissue: peripheral blood patient id: C1P2 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.5 cells per ml: 624750 purity (%): 96.0 rna integrity number: 8.3 age (years): 38 Sex: male body weight (in kg): 67 body size (in cm): 183 body mass index: 20.0 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 17 number of relapses in the past 2 years: 0 duration since last relapse (months): 206 edss score: 3.0 disease-modifying therapy: teriflunomide number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: better fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 6.18163
GSM8083299 patient C1P3, before first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 10.0 cells per ml: 498750 purity (%): 98.8 rna integrity number: 8.9 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 5.72337
GSM8083300 patient C1P3, after first course of MP, B cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.7 cells per ml: 383250 purity (%): 97.9 rna integrity number: 9.4 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 5.43856
GSM8083301 patient C1P3, before first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 31.0 cells per ml: 1134000 purity (%): 94.7 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.41981
GSM8083302 patient C1P3, after first course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 18.1 cells per ml: 640500 purity (%): 96.2 rna integrity number: 8.1 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.45007
GSM8083303 patient C1P3, before second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 30.3 cells per ml: 897750 purity (%): 97.0 rna integrity number: 8.5 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 6000 days from first to last mp 4.44713
GSM8083304 patient C1P3, after second course of MP, T cells tissue: peripheral blood patient id: C1P3 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 27.7 cells per ml: 1433250 purity (%): 97.5 rna integrity number: 8.3 age (years): 34 Sex: female body weight (in kg): 63 body size (in cm): 168 body mass index: 22.3 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 8 number of relapses in the past 2 years: 1 duration since last relapse (months): 5 edss score: 2.5 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 1 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 6000 days from first to last mp application: 5 side effects to mp: none 4.13246
GSM8083305 patient C1P4, before first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.3 cells per ml: 378000 purity (%): 96.3 rna integrity number: 9.6 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.86584
GSM8083306 patient C1P4, after first course of MP, B cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 7.5 cells per ml: 939750 purity (%): 96.7 rna integrity number: 8.8 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 5.90106
GSM8083307 patient C1P4, before first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 38.1 cells per ml: 1522500 purity (%): 98.7 rna integrity number: NA age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: 3.0 disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.98794
GSM8083308 patient C1P4, after first course of MP, T cells tissue: peripheral blood patient id: C1P4 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 15.9 cells per ml: 1617000 purity (%): 98.3 rna integrity number: 8.5 age (years): 53 Sex: female body weight (in kg): 58 body size (in cm): 159 body mass index: 22.9 current smoker: no study center: Berlin course of disease: CIS/RRMS disease duration (years): 3 number of relapses in the past 2 years: 0 duration since last relapse (months): 34 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 5 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 4.09515
GSM8083309 patient C1P5, before first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 31.6 cells per ml: 1344000 purity (%): 99.1 rna integrity number: 8.0 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 4.4459
GSM8083310 patient C1P5, after first course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 21.9 cells per ml: 1165500 purity (%): 98.9 rna integrity number: 8.4 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: none 4.28546
GSM8083311 patient C1P5, before second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 26.9 cells per ml: 1233750 purity (%): 97.8 rna integrity number: 8.5 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 4.26479
GSM8083312 patient C1P5, after second course of MP, T cells tissue: peripheral blood patient id: C1P5 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 11.0 cells per ml: 514500 purity (%): 98.6 rna integrity number: 8.7 age (years): 42 Sex: male body weight (in kg): 57 body size (in cm): 180 body mass index: 17.6 current smoker: yes study center: Berlin course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 7.5 disease-modifying therapy: ocrelizumab number of other medications taken: 6 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 4000 days from first to last mp application: 2 side effects to mp: cardiovascular problems 4.23155
GSM8083313 patient C2P1, before first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 11.7 cells per ml: 2604000 purity (%): 96.7 rna integrity number: 8.5 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.66937
GSM8083314 patient C2P1, after first course of MP, B cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 8.8 cells per ml: 630000 purity (%): 97.4 rna integrity number: 8.4 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 13.64744
GSM8083315 patient C2P1, before first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 41.5 cells per ml: 2436000 purity (%): 94.6 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 5.6702
GSM8083316 patient C2P1, after first course of MP, T cells tissue: peripheral blood patient id: C2P1 mp course: first time point: after cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 6.2 cells per ml: 346500 purity (%): 86.5 rna integrity number: 8.0 age (years): 24 Sex: female body weight (in kg): 60 body size (in cm): 170 body mass index: 20.8 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 6 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 5.44429
GSM8083317 patient C2P2, before first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.9 cells per ml: 467250 purity (%): 87.3 rna integrity number: 8.8 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: NA disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 13.32141
GSM8083318 patient C2P2, after first course of MP, B cells tissue: peripheral blood patient id: C2P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.3 cells per ml: 199500 purity (%): 97.6 rna integrity number: 9.5 age (years): 41 Sex: female body weight (in kg): 71 body size (in cm): 170 body mass index: 24.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 3 duration since last relapse (months): 3 edss score: 1.5 disease-modifying therapy: glatiramer acetate number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 17.12232
GSM8083319 patient C2P3, before first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 6.4683
GSM8083320 patient C2P3, after first course of MP, B cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 12.2 cells per ml: 1170750 purity (%): 97.2 rna integrity number: 8.5 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 9.00857
GSM8083321 patient C2P3, before first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 20.2 cells per ml: 1711500 purity (%): 94.3 rna integrity number: 7.3 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.74195
GSM8083322 patient C2P3, after first course of MP, T cells tissue: peripheral blood patient id: C2P3 mp course: first time point: before cell population: CD4+ T cells clinical evaluation: responder percentage in pbmc: 22.8 cells per ml: 992250 purity (%): 96.5 rna integrity number: 8.2 age (years): 20 Sex: female body weight (in kg): 55 body size (in cm): 165 body mass index: 20.2 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 6 number of relapses in the past 2 years: 0 duration since last relapse (months): NA edss score: 1.5 disease-modifying therapy: natalizumab number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 7.18753
GSM8083323 patient C2P4, before first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 8.0 cells per ml: 1690500 purity (%): 96.3 rna integrity number: 9.0 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 6.3738
GSM8083324 patient C2P4, after first course of MP, B cells tissue: peripheral blood patient id: C2P4 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 2.2 cells per ml: 273000 purity (%): 93.0 rna integrity number: 8.3 age (years): 60 Sex: male body weight (in kg): 97 body size (in cm): 170 body mass index: 33.6 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 7 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: peginterferon beta-1a number of other medications taken: 8 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 10.36683
GSM8083325 patient C2P5, before first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.6 cells per ml: 136500 purity (%): 53.8 rna integrity number: 6.9 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 13.01366
GSM8083326 patient C2P5, after first course of MP, B cells tissue: peripheral blood patient id: C2P5 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.8 cells per ml: 687750 purity (%): 98.1 rna integrity number: 8.2 age (years): 59 Sex: female body weight (in kg): 60 body size (in cm): 172 body mass index: 20.3 current smoker: yes study center: Greifswald course of disease: CIS/RRMS disease duration (years): 4 number of relapses in the past 2 years: 1 duration since last relapse (months): 22 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: better fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 4 side effects to mp: none 9.7332
GSM8083327 patient C2P6, before first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 4.2 cells per ml: 546000 purity (%): 92.4 rna integrity number: 8.8 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: 6.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 5.49793
GSM8083328 patient C2P6, after first course of MP, B cells tissue: peripheral blood patient id: C2P6 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 6.6 cells per ml: 714000 purity (%): 97.8 rna integrity number: 9.0 age (years): 39 Sex: female body weight (in kg): 54 body size (in cm): 164 body mass index: 20.1 current smoker: no study center: Greifswald course of disease: CIS/RRMS disease duration (years): 18 number of relapses in the past 2 years: 0 duration since last relapse (months): 47 edss score: NA disease-modifying therapy: dimethyl fumarate number of other medications taken: 3 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 5.35194
GSM8083329 patient C2P7, before first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.7 cells per ml: 215250 purity (%): 95.6 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: yes fs: cerebellar: no fs: cerebral: yes fs: pyramidal: no fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 5.83326
GSM8083330 patient C2P7, after first course of MP, B cells tissue: peripheral blood patient id: C2P7 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 2.8 cells per ml: 162750 purity (%): 93.2 rna integrity number: 7.8 age (years): 36 Sex: male body weight (in kg): 90 body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 16 number of relapses in the past 2 years: 1 duration since last relapse (months): 21 edss score: 3.0 disease-modifying therapy: none number of other medications taken: 1 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: better fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 2 side effects to mp: none 7.74156
GSM8083331 patient C2P8, before first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 3.5 cells per ml: 220500 purity (%): 95.5 rna integrity number: 8.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: 2.0 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: no total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 4.24043
GSM8083332 patient C2P8, after first course of MP, B cells tissue: peripheral blood patient id: C2P8 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: non-responder percentage in pbmc: 11.0 cells per ml: 535500 purity (%): 97.3 rna integrity number: 7.5 age (years): 23 Sex: female body weight (in kg): NA body size (in cm): NA body mass index: NA current smoker: NA study center: Greifswald course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 1 duration since last relapse (months): 10 edss score: NA disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 3000 days from first to last mp application: 2 side effects to mp: none 6.39191
GSM8083333 patient C3P1, before second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: before cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 24.0 cells per ml: 225750 purity (%): 97.0 rna integrity number: 7.9 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: no fs: sensory: yes fs: visual: yes total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 5.42763
GSM8083334 patient C3P1, after second course of MP, T cells tissue: peripheral blood patient id: C3P1 mp course: second time point: after cell population: CD4+ T cells clinical evaluation: non-responder percentage in pbmc: 10.1 cells per ml: 315000 purity (%): 98.6 rna integrity number: 8.3 age (years): 36 Sex: female body weight (in kg): 63 body size (in cm): 175 body mass index: 20.6 current smoker: yes study center: Jena course of disease: CIS/RRMS disease duration (years): 0 number of relapses in the past 2 years: 2 duration since last relapse (months): NA edss score: 2.5 disease-modifying therapy: dimethyl fumarate number of other medications taken: 0 neurological dysfunction: recurring fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: unchanged fs: sensory: better fs: visual: worse total dose of mp in mg: 10000 days from first to last mp application: 6 side effects to mp: none 6.84016
GSM8083335 patient C4P1, before first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 5.3 cells per ml: 336000 purity (%): 96.3 rna integrity number: 9.4 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: no fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: yes fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 4.8096
GSM8083336 patient C4P1, after first course of MP, B cells tissue: peripheral blood patient id: C4P1 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 6.9 cells per ml: 1417500 purity (%): 96.1 rna integrity number: 8.7 age (years): 45 Sex: male body weight (in kg): 90 body size (in cm): 180 body mass index: 27.8 current smoker: yes study center: Rostock course of disease: CIS/RRMS disease duration (years): 13 number of relapses in the past 2 years: 0 duration since last relapse (months): 166 edss score: 3.5 disease-modifying therapy: none number of other medications taken: 0 neurological dysfunction: new fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 5 side effects to mp: hyperhidrosis 6.88049
GSM8083337 patient C4P2, before first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: before cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: NA cells per ml: 493500 purity (%): 94.2 rna integrity number: 8.2 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 7.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: yes fs: brainstem: no fs: cerebellar: no fs: cerebral: no fs: pyramidal: yes fs: sensory: no fs: visual: no total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 6.70502
GSM8083338 patient C4P2, after first course of MP, B cells tissue: peripheral blood patient id: C4P2 mp course: first time point: after cell population: CD19+ B cells clinical evaluation: responder percentage in pbmc: 0.4 cells per ml: 236250 purity (%): 42.7 rna integrity number: 8.1 age (years): 54 Sex: female body weight (in kg): 93 body size (in cm): 173 body mass index: 31.1 current smoker: no study center: Rostock course of disease: SPMS disease duration (years): 20 number of relapses in the past 2 years: 1 duration since last relapse (months): 11 edss score: 6.5 disease-modifying therapy: none number of other medications taken: 3 neurological dysfunction: NA fs: bladder or bowel: unchanged fs: brainstem: unchanged fs: cerebellar: unchanged fs: cerebral: unchanged fs: pyramidal: better fs: sensory: unchanged fs: visual: unchanged total dose of mp in mg: 5000 days from first to last mp application: 6 side effects to mp: none 7.01601

ID GSE4386
Title Transcriptomics in cardiac surgery
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM99229 H01_S_B1 male CABG patient, atrial tissue baseline before CABG surgery 16.4768690525
GSM99235 H01_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 8252.15811325
GSM99239 H02_P_B1 male CABG patient, atrial tissue baseline before CABG surgery 9.0003581865
GSM99241 H02_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 6546.22249705
GSM99244 H03_P_B1 male CABG patient, atrial tissue baseline before CABG surgery 6.911609081
GSM99246 H03_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 3201.7796254000004
GSM99247 H04_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 15.722065024499999
GSM99249 H04_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 2859.5480077849998
GSM99252 H05_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 12.8988405305
GSM99253 H05_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 4342.88189175
GSM99255 H06_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 17.672223308
GSM99257 H06_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 2187.7525854299997
GSM99258 H07_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 44.949956911499996
GSM99259 H07_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 2401.75397112
GSM99261 H08_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 26.748542709
GSM99265 H08_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 3721.4149248999997
GSM99268 H09_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 14.9309651265
GSM99271 H09_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 1195.39130809
GSM99274 H10_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 6.628654241
GSM99277 H10_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 2099.082190955
GSM99280 H11_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 14.109252093
GSM99282 H11_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 14508.3232685
GSM99285 H12_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 10.6948809865
GSM99287 H12_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 1999.642476895
GSM99289 H13_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 39.699595394
GSM99290 H13_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 1264.5024799
GSM99291 H14_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 8.770336865
GSM99292 H14_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 2482.33958385
GSM99293 H15_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 7.7960577545
GSM99294 H15_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 1059.722828215
GSM99295 H16_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 7.333730770500001
GSM99296 H16_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 1886.832016555
GSM99298 H17_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 10.3317739385
GSM99299 H17_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 9008.122011899999
GSM99301 H18_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 12.360836951
GSM99302 H18_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 780.41796419
GSM99303 H19_P_B1 male CABG patient, atrial tissue, baseline before CABG surgery 15.332007892
GSM99304 H19_P_B2 male CABG patient, atrial tissue, propofol anesthesia, after CABG surgery 1038.687144901
GSM99305 H20_S_B1 male CABG patient, atrial tissue, baseline before CABG surgery 15.842048909
GSM99306 H20_S_B2 male CABG patient, atrial tissue, sevoflurane anesthesia, after CABG surgery 10399.81494105

ID GSE59526
Title Affymetrix Chip data of the transcriptome of human clinical study for acupuncture mechanisms on rheumatoid arthritis
Organism Homo sapiens
GSM Sample info Characteristics Value
GSM1438864 Peripheral blood mononuclear cells from AP group, Patient 2 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: before therapy patient id: 2 5807.04174095
GSM1438865 Peripheral blood mononuclear cells from AP group, Patient 3 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: before therapy patient id: 3 1357.9219492500001
GSM1438866 Peripheral blood mononuclear cells from AP group, Patient 6 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: before therapy patient id: 6 14823.374328999998
GSM1438867 Peripheral blood mononuclear cells from AP group, Patient 8 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: before therapy patient id: 8 1677.7590012
GSM1438868 Peripheral blood mononuclear cells from AP group, Patient 9 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: before therapy patient id: 9 1556.95563195
GSM1438869 Peripheral blood mononuclear cells from MTX group, Patient 4 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: before therapy patient id: 4 30568.953629999996
GSM1438870 Peripheral blood mononuclear cells from MTX group, Patient 5 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: before therapy patient id: 5 55.112382545
GSM1438871 Peripheral blood mononuclear cells from MTX group, Patient 7 before therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: before therapy patient id: 7 4898.505714749999
GSM1438872 Peripheral blood mononuclear cells from Patient 1 after 2 weeks acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 1 1709.3540118
GSM1438873 Peripheral blood mononuclear cells from Patient 3 after 2 weeks acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 48 treatment group: acupuncture+methotrexate time point: after 2 weeks therapy patient id: 3 4833.72873995
GSM1438874 Peripheral blood mononuclear cells from Patient 1 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 64 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 1 1311.77354642
GSM1438875 Peripheral blood mononuclear cells from Patient 2 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 53 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 2 2319.4511911
GSM1438876 Peripheral blood mononuclear cells from Patient 6 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 36 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 6 1048.7306334999998
GSM1438877 Peripheral blood mononuclear cells from Patient 8 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 60 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 633.1744937269999
GSM1438878 Peripheral blood mononuclear cells from Patient 9 after 3 months acupuncture therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 31 treatment group: acupuncture+methotrexate time point: after 3 months therapy patient id: 9 1622.4155252
GSM1438879 Peripheral blood mononuclear cells from Patient 4 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 61 treatment group: methotrexate time point: after 3 months therapy patient id: 4 286.08082519
GSM1438880 Peripheral blood mononuclear cells from Patient 5 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 49 treatment group: methotrexate time point: after 3 months therapy patient id: 5 1624.45415265
GSM1438881 Peripheral blood mononuclear cells from Patient 7 after 3 months MTX therapy cell type: peripheral blood mononuclear cells disease state: rheumatoid arthritis gender: female age: 35 treatment group: methotrexate time point: after 3 months therapy patient id: 7 132.680852525